Physician profile
Sudhakar Reddy
NPI 1063458735
$9,515.50
in general payments reported to CMS, 2019-2025
37 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $1,185 · 2021: $1,281 · 2022: $1,744 · 2023: $2,434 · 2024: $1,858 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,439 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,439.30 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,011.37 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,285.29 | 2019-2024 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $781.11 | 2019-2024 | |
| Gilead Sciences, INC. | $723.57 | 2019-2025 | |
| Janssen Biotech, INC. | $350.16 | 2020-2023 | Stelara |
| Merck Sharp & Dohme LLC | $237.70 | 2019-2024 | Dificid |
| Qol Medical, LLC | $220.27 | 2019-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $202.76 | 2023-2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $168.12 | 2020-2024 | Eohilia, Gattex |
| Dilon Technologies, INC. | $148.27 | 2024 | Hemoblast Bellows |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Celgene Corporation | $113.49 | 2021-2024 | Zeposia |
| Organon LLC | $112.03 | 2023-2024 | Renflexis, Hadlima |
| Regeneron Healthcare Solutions, INC. | $105.92 | 2022-2024 | Dupixent |
| Lucid Diagnostics INC. | $93.08 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $88.40 | 2021-2024 | Linzess |
| Ambu INC. | $85.17 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $83.91 | 2019-2024 | Ocaliva |
| Medtronic, INC. | $76.19 | 2021-2023 | Interstim |
| Mylan Institutional INC. | $71.15 | 2023 | Hulio |
| Nestle Healthcare Nutrition INC. | $54.55 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $49.12 | 2024 | Voquezna |
| Redhill Biopharma INC. | $48.84 | 2021-2023 | Talicia |
| Ardelyx, INC. | $47.26 | 2023-2024 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $41.78 | 2024 | Iqirvo, Bylvay |
| Sirtex Medical INC | $25.28 | 2025 | Sir-Spheres Microspheres |
| Mauna Kea Technologies, INC. | $23.41 | 2025 | |
| Allergan, INC. | $23.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.66 | 2023 | Cyltezo |
| Ucb, INC. | $18.84 | 2019 | |
| Pharmacosmos Therapeutics INC. | $16.94 | 2023 | Monoferric |
| Oxford Immunotec USA INC | $15.12 | 2021 | |
| Biotronik INC. | $13.95 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.03 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhakar Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.